See Our Traction

ReRx Development Timeline

Since our inception, we have achieved significant milestones in drug discovery and validation, patent filings, and partnerships. Our commitment to advancing metabolic disease therapeutics have led to breakthroughs in reshaping the future of metabolic disease therapeutics.

Our leading indication from our lead candidate, ReRx-001 is addressing obesity with expansion to associated co-morbidities such as fatty liver disease, metabolic syndrome, and Type 2 diabetes. Through strategic collaborations and discovery approaches, we are continuing to develop novel therapeutic approaches to address severe metabolic diseases.